Jci_page_head_homepage_01 Jci_page_head_homepage_02
Veronica Marrella, Pietro Luigi Poliani, Anna Casati, Francesca Rucci, Laura Frascoli, Marie-Lise Gougeon, Brigitte Lemercier, Marita Bosticardo, Maria Ravanini, Manuela Battaglia, Maria Grazia Roncarolo, Marina Cavazzana-Calvo, Fabio Facchetti, Luigi D. Notarangelo, Paolo Vezzoni, Fabio Grassi, Anna Villa
Published in Volume 117, Issue 5
J Clin Invest. 2007; 117(5):1260–1269 doi:10.1172/JCI30928
Abstract | Full text | PDF | Supplemental material
Options: View larger image (or click on image)
Medium
Figure 1
Generation of Rag2R229Q/R229Q ES cells and mice.

(A) A targeting vector was designed to replace endogenous Rag2 with the gene carrying the R229Q substitution and an NheI restriction site. GFP was fused in frame with the Rag2 neo cassette flanked by loxP sites (arrows), which was cloned downstream of the Rag2 UTR (black box). Gray boxes denote the 3′ probe used for genomic screening. (B) Southern blot analysis using the 3′ probe on EcoRV-digested genomic DNAs. Lane 1, 129Sv wild-type ES cells; lane 2, Rag2+/R229QneoΔ recombinant ES cells; lane 3, heterozygous Rag2+/R229QneoΔ mouse after neo excision due to Cre cross; lane 4, 129Sv Rag2+/+ mouse; lane 5, Rag2+/R229QneoΔ mouse. (C) Chromatogram showing nucleotide substitutions, denoted by underline: the first 2 changes obtained the NheI restriction site, the last 2 caused the R to Q amino acid change (bold).